Beyond A1C: Understanding the Growing Toolkit of Glucose Metrics

For decades, hemoglobin A1C was the primary tool for measuring long-term blood sugar control. But A1C has limitations: it shows only an average over three months and misses the ups and downs that happen daily. Continuous glucose monitors changed that by collecting glucose readings every few minutes, 24 hours a day.

This richness of data opens new possibilities. Clinicians can see not just whether someone's average is good, but how often they're experiencing highs and lows, how quickly their glucose swings, and whether patterns vary by time of day or day of the week. Researchers can use this detail to design more precise trials and measure how well treatments actually work. But with opportunity comes complexity: the field now has dozens of different ways to measure glucose control, and not everyone is measuring the same thing in the same way.

A recent literature review organized CGM metrics into four broad categories. Standardized metrics are the established measures most clinicians know, like average glucose and time in range. Clinical metrics go deeper—measuring things like glucose variability or how often someone experiences dangerous lows. Emerging metrics explore newer dimensions of glucose behavior that may help identify risk or guide treatment adjustments. Composite metrics combine several measures into a single score, offering a more complete picture of control.

The distinction matters because a metric useful for a doctor's daily decision-making may not be the right choice for a research study testing a new treatment. And vice versa: a research metric designed to capture fine details of glucose behavior might be too complex or unstable to rely on in clinic.

One major problem facing the field: the same metric can be calculated differently depending on which CGM device someone uses, which software analyzes the data, and even which research team is doing the work. This makes it hard to compare results across studies or to confidently use new metrics in clinical practice.

The diabetes research community is working to address this. Researchers have identified 27 key metrics and are developing clearer definitions for how they should be calculated and interpreted. The goal is to ensure that when researchers or clinicians talk about 'time in range' or 'glucose variability,' everyone means the same thing—measured the same way.

If you're using a CGM, you've likely seen numbers and charts your care team discusses. As metrics become more standardized and better understood, your clinician may have new tools to spot patterns and make treatment adjustments tailored to your specific glucose behavior. In research, clearer metrics mean trials can better measure whether new treatments actually work.

For now, the key takeaway is simple: glucose control is multidimensional. A1C matters, but it's only part of the story. The work underway to standardize and clarify CGM metrics reflects the field's commitment to using all the data available to help people with Type 1 diabetes thrive.

Source: JMIR diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.